Sanofi received orphan designation from the European Medicines Agency (EMA).
3 reports, 3 independent
Updated Aug 26
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Sanofi received orphan designation from the European Medicines Agency (EMA).
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
EMA
Japanese vocalist of the group DUSTCELL
Nothing else this week.
-
Sanofi
company in Milan, Italy
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- Insider MonkeySanofi (SNY) Receives Orphan Designation for Rilzabrutinib Sanofi (NASDAQ:SNY) is one of the Most Undervalued International Stocks According to Analysts. On August 14, Sanofi (NASDAQ:SNY) announced r
- Pharmaceutical TechnologySanofi receives orphan status from EMA for rilzabrutinib Sanofi has received orphan designation from the European Medicines Agency (EMA) for rilzabrutinib, a reversible covalent Bruton’s tyrosine kin
- GlobeNewswirePress Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the posi